15,547 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Purchased by Intech Investment Management LLC

Intech Investment Management LLC acquired a new stake in shares of Acelyrin, Inc. (NASDAQ:SLRN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,547 shares of the company’s stock, valued at approximately $77,000.

Other hedge funds have also added to or reduced their stakes in the company. Millennium Management LLC boosted its stake in shares of Acelyrin by 15.7% during the 2nd quarter. Millennium Management LLC now owns 4,642,056 shares of the company’s stock worth $20,471,000 after acquiring an additional 628,528 shares during the last quarter. Blue Owl Capital Holdings LP increased its stake in shares of Acelyrin by 3.5% in the second quarter. Blue Owl Capital Holdings LP now owns 2,926,028 shares of the company’s stock worth $12,904,000 after purchasing an additional 100,000 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Acelyrin by 218.0% during the 2nd quarter. Renaissance Technologies LLC now owns 397,618 shares of the company’s stock valued at $1,753,000 after buying an additional 272,600 shares in the last quarter. Almitas Capital LLC bought a new position in Acelyrin in the 2nd quarter worth $1,659,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Acelyrin by 22.5% in the second quarter. Bank of New York Mellon Corp now owns 223,395 shares of the company’s stock valued at $985,000 after acquiring an additional 41,058 shares in the last quarter. 87.31% of the stock is currently owned by hedge funds and other institutional investors.

Acelyrin Stock Performance

Shares of NASDAQ SLRN opened at $4.25 on Monday. The business’s 50 day moving average price is $5.30 and its 200-day moving average price is $5.02. The company has a market cap of $426.39 million, a price-to-earnings ratio of -1.73 and a beta of 1.61. Acelyrin, Inc. has a fifty-two week low of $3.36 and a fifty-two week high of $8.89.

Wall Street Analyst Weigh In

Several research firms recently issued reports on SLRN. Morgan Stanley cut their target price on Acelyrin from $13.00 to $6.00 and set an “equal weight” rating for the company in a research report on Monday, August 19th. HC Wainwright raised their target price on shares of Acelyrin from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Thursday, November 14th. Piper Sandler decreased their target price on Acelyrin from $68.00 to $20.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. Finally, Wells Fargo & Company increased their price objective on shares of Acelyrin from $13.00 to $15.00 and gave the company an “overweight” rating in a research report on Wednesday, October 16th.

Acelyrin Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.